Esta página web usa cookies. ¿Acepta usted el uso de cookies externos? No Saber más x
Encuesta sobre la acondroplasia
Hemos diseñado un cuestionario con el objetivo de conocer la población afectada o cercana a la acondroplasia.
El cuestionario es opcional y anónimo. Los datos obtenidos serán usados para cálculos estadísticos y para poder tener una mejor percepción sobre la historia natural de la acondroplasia.
Por favor, considere e intente responder. Si usted desea responder a las preguntas más tarde, puede presionar el botón en la parte superior "Inscribirse en BA"

The Pros and Cons in each different treatment for Achondroplasia

2021-07-14Research
This recent study by Dr. Wiktoria Wrobel (Medical University of Lublin, Poland) brings together the different pharmacological treatments for achondroplasia, both current and potential, highlighting the advantages and disadvantages of each, making it a great comprehensive review.

Assessing the impacts of having a child with achondroplasia on parent well‑being

2021-06-15Research
A paper1 on a Quality of Life research study conducted by Kathryn M. Pfeifer et al aims to develop a better understanding of the experiences of parents of children with achondroplasia.

How does gait differ in children with achondroplasia?

2021-03-12Research
What is still to be understood on how gait in children with achondroplasia is altered compared to average height children. 

What is still to be known about achondroplasia

2021-03-12Research
A recently published article by Julie Hoover-Fong et al.1 seeks to synthesize the current knowledge base about the nature, incidence, chronology, and the interrelationships of achondroplasia-related comorbidities across the lifespan.

New potential treatment for achondroplasia by the Tsumaki lab & Astellas Pharma Inc.

2020-12-27Research
The Tsumaki lab, at the Center for iPS Cell Research and Application (CiRA), Kyoto University, is leading new research for achondroplasia with ASP5878, an FGFR inhibitor, using iPS cells. This is a study in collaboration with Astellas Pharma.

First children with achondroplasia receive Recifercept

2020-12-16Research
Pfizer released a Press Statement of the first children with achondroplasia receiving Recifercept, initiating the Phase 2 clinical trial
Para ver esta página web usted necesita de Internet Explorer 8 (o una versión más reciente)
u otro browser.


Muchas gracias.